Technical Data
L2601-12A
Lipoprotein, Low Density, Human (LDL)
10mg
100mg
Molecular Biology Storage: -70CShipping: Blue Ice
Human LDL produced in Human plasma. HDL/LDL ratio can give an indication of Source:risk for arteriosclerosis.

LDL constitutes 50% of the total lipoprotein mass in plasma and is the major carrier of cholesterol and cholesteryl esters. LDL levels strongly correlate with coronary heart disease. Cholesterol is an important normal constituent of the body. It is part of the structure of cell membranes, bile acids and steroid hormones. Since cholesterol is water insoluble, most cholesterol is carried in the blood by lipoproteins. Lipoproteins are large protein-like molecules, including chylomicrons, VLDL, LDL and HDL. Chylomicrons are lipoproteins that are present shortly after a meal. They disappear within about 2 hours in "normal" people. The main function of LDL seems to be to carry cholesterol to various tissues throughout the body. LDL is sometimes referred to as "bad" cholesterol because elevated levels of LDL correlate most directly with coronary heart disease.

Storage and Stability:
May be stored at -20C for short-term only. Aliquot to avoid repeated freezing and thawing and store at -70C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Source: Human plasma
Concentration: As reported
Form: As Reported

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Protective effects of endomorphins, endogenous opioid peptides in the brain, on human low density lipoprotein oxidation. FEBS J 2006 Mar;273(6):1275-84. 2. Human low-density lipoprotein receptor gene and its regulation. J Mol Med 2006 Jan;84(1):29-36. 3. Lipid-soluble 3-pyridinol antioxidants spare alpha-tocopherol and do not efficiently mediate peroxidation of cholesterol esters in human low-density lipoprotein.
J Med Chem 2005 Nov 3;48(22):6787-9 4. Additive or synergetic effects of phenolic compounds on human low density lipoprotein oxidation. Food Chem Toxicol 2006 Apr;44(4):510-6. 5. Lipid composition influences the shape of human low density lipoprotein in vitreous ice. Lipids 2005 May;40(5):495-500. 6. Policosanol has no antioxidant activity in human low-density lipoprotein but increases excretion of bile acids in hamsters. J Agric Food Chem 2005 Aug 10;53(16):6289-93

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.